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comparison with similar patients receiving NST or RIC regimens is
warranted.331
ASSOCIATION BETWEEN THE HEMATOPOIETIC CELL TRANSPLANTA-
TION-SPECIFIC COMORBIDITY INDEX (CIN) AND NON-RELAPSE MOR-
TALITY (NRM) AFTER REDUCED INTENSITY CONDITIONING (RIC)
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR ACUTE
MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR1)
Mohty, M., Labopin, M., Basara, N., Cornelissen, J., Tabrizi, R.,
Malm, C., Perez-Simon, J.A., Nagler, A., Kroger, N., Rio, B.,
Martino, R., Eder, M., Bilger, K., Bunjes, D.W., Socie, G., Blaise, D.,
Polge, E., Rocha, V. On behalf of the Acute Leukemia Working Party
(ALWP) of EBMT
The adapted Charlson CIn (Sorror-CIn) was useful for predicting
NRM and survival in allo-SCT patients. However, the value of this
CI index is still under considerable debate, since the cohort used by
Sorror et al. (Blood 2005) included a heterogeneous group of pa-
tients. On the other hand, toxicities and NRM prediction is most
likely needed in elderly and medically infirm patients who are in-
creasingly offered RIC allo-SCT. Thus, the current study was de-
signed to test the performance of this CI and its association with
outcomes among a cohort of 345 patients (i) aged .50 y.; (ii) diag-
nosed with a single disease entity, AML in CR1, and (iii) who under-
went a RIC allo-SCT reported to the EBMT registry.
In this series, the median age was 58 y. (range, 50-76). A fludara-
bine-based RIC regimen was used in 64% of patients, while 31% re-
ceived low-dose TBI as part of their RIC, and 6% received other
non-specified RIC regimens. 76% of the patients received allo-
SCT from an HLA-matched sibling donor.
Based on score calculated with HR estimated on the population
studied, 161 patients (47%) had aCIn score of 0, 96 (29%) had a score
of 1, and 49 (14%) had a CI score of 2. 39 patients (11%) had CI
scores of 3 or more. In this cohort, 2 y. overall and LFS rates were
646 3% and 546 3% and the 2 y. relapse and -NRMcumulative in-
cidences (CI) were 326 2%, and 156 2% respectively. The 2 y.
NRM CI according to comorbidities score 0, 1, 2 and 3+ were
96 2%, 156 4%, 186 5% and 316 7%, respectively. In multivar-
iate models (adjusted for age, donor type, use of TBI or not, and cy-
togenetics risk group) comorbidities such as moderate active liver
disease, obesity, prior history of renal dysfunction, and prior history
of severe liver disease were associated with the highest HRs for 2 y.
NRM (varying from 2.11 to 2.76) and 2 y. CI of NRM varying from
22% to 44%, whereas previous solid tumor, diabetes, rheumatologic
abnormalities, moderate pulmonary diseases, cardiac abnormalities
(other than arrhythmia and valve disease) were associated with the
lowest HRs (varying from 0.2 to 1.0) with 2 y. CI of NRM varying
from 5 to 17%.
Results from this study performed in a single disease entity, sug-
gest that the hematopoietic cell transplantation-specific CIn is an in-
formative and useful tool for capturing pre-transplant comorbidities,
and for predicting NRM after RIC allo-SCT for AML in CR1 in
patients aged .50 y. Such index may be used for clinical trials and
patient counselling before RIC allo-SCT.332
A NOVEL REDUCED TOXICITY PREPARATIVE REGIMEN FOR HEMATO-
POIETIC CELL ALLOGRAFTING COMBINING PENTOSTATIN (NIPENT)
AND TARGETED DOSES OF INTRAVENOUS BUSULFAN (BUSULFEX)
WITH OR WITHOUT RITUXIMAB (PB6 R) USING CD4-GUIDED IMMUNE
SUPPRESSION: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE
TRIAL
Kharfan-Dabaja, M.A.1, Perkins, J.1, Cortes, R.1, Brand, L.1,
Fernandez, H.F.1, Ochoa-Bayona, J.L.1, Field, T.1, Perez, L.1,
McIsaac, C.1, Maddox, B.1, Ayala, E.1, Komrokji, R.2, Pinilla-
Ibarz, J.2, Sotomayor, E.2, Tomblyn, M.1, Anasetti, C.1 1H. Lee Moffitt
Cancer Center, Tampa, FL; 2H. Lee Moffitt Cancer Center, Tampa, FL
This reduced toxicity regimen evaluates CD4-guided immune
suppression to facilitate early robust CD3 donor engraftment. Itconsists of a pre-conditioning treatment phase with Pentostatin
4 mg/m2 (days -28, -21, -14) if host CD4 counts are .100/uL; and
Rituximab 375 mg/m2 (days -21, -14, -7) in CD20+ lymphoid malig-
nancies. Conditioning phase consists of Pentostatin 4 mg/m2 (days
-4,-3) and two doses of I.V Busulfan (1st dose5 200 mg/m2 (day
-4) and 2nd dose (day-2)5 adjusted for cum. AUC5 16,000 micro-
mol*min/L 610%). Pts with CD20+ disease receive Rituximab
(375 mg/m2 on +1, +8). Primary study endpoint is$ 50% donor chi-
merism by day +28 (67) in CD3 + PB lymphocytes. At time of this
report 25 pts, M/F5 19/6, median age 56 (40-72) years, were evalu-
able. Diagnoses included 8 CLL (1 PR1, 1 CR2, 1 PR2, 5$ PR3), 4
mantle cell (1CR2, 2 PR2, 1 PR3), 4 follicular NHL (1CR2, 1 PR2,
1CR3, 1PR4), 2 Richter’s (1. PR2, 1CR3), 2 AML(1CR1, 1 PIF), 1
MDS (Persistent), 1 B-PLL (PR2), 1 T-cell NHL-NOS (PR2), 1 T-
PLL (PR1), and 1Waldestrom’s (PR1). Median (range) CD4 levels/
uL on days -28, -21, -14, -7, and 0 were 368 (27-842), 172 (33-571),
116 (41-277), 130 (43-344) and 34 (9-161), respectively. Median
(range) AUC for 1st, 2nd, and cum. Busulfan dose were 8,374
(6,058-11,124), 9,032 (5,432-13,215), and 17,567 (15,010-21,215),
respectively. All received G-CSF mobilized PBSC from 13 MRD,
7 MUD, 5 MMUD (B Ag5 2; C Ag5 1; DQ Ag5 2). Median
CD34+ dose infused was 9.01 (3.38-10.03) x106/kg cells. GVHD
prophylaxis was TAC-MTX in 21 (84%) and TAC-SIR in 4
(16%). No ATG was administered. Median (range) days to ANC
and PLAT engraftment were 17 (8-28) and 16 (10-33), respectively.
Twelve pts (48%) did not drop PLAT\20 K/uL. Median (range)
donor CD3, CD33 and unsorted BM chimerisms on day 28 (67
days) were 86% (59%-100%), 100% (95%-100%), 95% (90%-
100%), respectively (table 1). Non-relapse mortality at 100 days,
180 days, and at median F/U [269 (39-564) days] were 0%, 4%,
and 12%, respectively. One pt (MDS) died of progression. There
was no evidence of EBV reactivation or PTLD. aGVHD (max grade)
was: 05 4 (16%), I5 9 (36%), II5 9 (36%), III-IV5 3 (12%).
cGVHD by NIH consensus in 21 evaluable pts was: none5 5
(23.8%), mild5 5 (23.8%), mod5 8 (38.1%), and severe5 3
(14.3%). All but 5 pts received Rituximab making it not possible to
comment on its impact on GVHD at this time. PB6R is a safe reg-
imen that ensures early durable donor CD3 engraftment with mini-
mal NRM. Data will be updated at presentation.
Table 1.
Day 286 7 Day 906 7% Donor engraftment
by STR/PCR Median (range) Median (range)CD3 86% (59%-100%) 96% (77%-100%)
CD33 100% (95%-100%) 100% (100%-100%)
Unsorted BM 95% (90%-100%) 96% (78%-100%333
FREQUENCY OF ALLOGENEIC STEM CELL TRANSPLANT (SCT) IN PA-
TIENTS PRESENTING WITH NEWLY-DIAGNOSED AML OR AML AT TIME
OF FIRST SALVAGE THERAPY
Sandhu, R., Petersdorf, S., Sandmaier, B.M., O’Donnell, P., Becker, P.S.,
Deeg, H.J., Appelbaum, F.R., Estey, E.H. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Allogeneic SCT is widely considered the therapy most likely to
prolong survival in pts with AML in first complete remission
(CR1) or relapse (REL). Questions have arisen regarding the fre-
quency with which the procedure is undertaken in a defined popu-
lation of pts presenting with newly-diagnosed AML and
subsequently followed through REL and after, or in pts presenting
in REL. We first analyzed 26 consecutive pts age\70 who did not
have CBF AML, who were not NPM1+/FLT3-, and who achieved
CR1 with at least 4 months have elapsing from presentation date.
These patients would typically be considered candidates for SCT
in CR1. Eleven of the 26 (42%, 95% CI 23-63%) received SCT
at a median of 3.5 months (range 0.5-9.0) from CR date. Rates
S282 Poster Session IIof SCT were 42% both in pts age\60(8/19) and in pts$ 60 (3/7).
In contrast to a report from another institute in which 14/99 pts
age $50 received SCT in CR, 7/16 in this current study did so
(p5 0.01). Rates of SCT were 6/13 in pts at highest risk based
on cytogenetics and FLT3 status and 3/11 in pts at lower (i.e. ‘‘in-
termediate’’ risk; risk status not known in 2) Three of the 15 pts
who did not receive SCT had available donors, but 12 were not
HLA -typed. Age distribution was similar (p5 0.31) in pts who
were and were not HLA-typed and in only 2 non-typed pts were
financial considerations or pt refusal an issue. Rather, notes sug-
gested that physicians felt that pts were doing well and might not
need SCT. We also examined our 21 consecutive pts who were un-
der age 70, did not receive SCT in CR1, and were given first sal-
vage therapy (S1) for relapse, again with at least 4 months
follow-up from relapse date. These 21 included patients referred
to us at initial diagnosis or only at time of S1. The frequency
with which they were transplanted (8/21; 38% 95% CI 18-62%)
did not differ from the frequency with which SCT was done in
CR1. However SCT was most commonly done as 2nd salvage ther-
apy (4 cases), with 3 pts transplanted in CR2 or CR and only 1
given SCT as S1. Ten of the 13 S1 pts never given SCT had avail-
able donors (3 related, 3 unrelated, 4 cord) and SCT was not done
because of high blasts and/or poor performance status. We con-
clude that although older and younger pts may be equally likely
to receive SCT in CR1, failure to HLA type may be a major im-
pediment to improving rates of SCT in CR1. Although relapsed
pts are transplanted as often as pts in CR1, such transplants are
only rarely used as initial therapy of relapse.334
HIGHER RATES OF FATAL BACTERIAL AND INVASIVE FUNGAL INFEC-
TIONS, BUT NO DIFFERENCE IN CYTOMEGALOVIRUS (CMV) REACTIVA-
TION SEEN WITH THE USE OF ALEMTUZUMAB IN A REDUCED
INTENSITY CONDITIONING REGIMEN
Shabbir, M., Costa, L., Fouts, T.V., Schaub, C., Kistner-Griffin, E.,
Maxwell, C., Rogers, K., Stuart, R.K. Medical University of South Caro-
lina, Charleston, SC
Background: Reduced intensity conditioning (RIC) for allogeneic
hematopoietic stem cell (HSC) transplantation is a well established
therapy for patients with advanced hematological malignancies.The
use of Alemtuzumab as part of RIC has been associated with decrease
in incidence and severity of graft versus host disease (GVHD), par-
ticularly in unrelated donor transplants.
Methods: This is a single center, prospective study. Patients who
were not candidates for full myeloablative conditioning regimens re-
ceived an non-Alemtuzumab (nA) containing RIC regimen or an
Alemtuzumab-containing regimen (A) based on the use of a matched
sibling or an unrelated donor, respectively. Patients in the nA group
were conditioned with either Fludarabine and total body irradiation
or Fludarabine and Melphalan. Patients in the A group received
Alemtuzumab,Fludarabine and Melphalan. All patients received tri-
methoprim/sulphamethoxazole for PCPprophylaxis, fluconazole for
fungal prophylaxis and acyclovir for viral prophylaxis. Treatment for
CMV reactivation was preemptively initiated with gancyclovir or
valgancyclovir when documented by positive CMV PCR in periph-
eral blood. Supportive care was standard across both groups.
Results: From January 2003 to March 2009, 56 patients were en-
rolled in the study and 50 patients went on to receive an HSCT
and are the subject of this analysis. Twenty nine patients were in-
cluded on group nA and 21 in group A. Median age of the patients
in the entire cohort was 55 years (range 14-65). Twenty four patients
in nA group and 16 patients in A group were considered high risk for
CMV reactivation post transplant because of donor and/or recipient
positive CMV serological status. Rates of CMV reactivation was
similar between the two groups (75% in nA and 67% in A,
P5 0.19). Two patients developed CMV pneumonitis, and one de-
veloped CMV colitis in the A group and were successfully treated
with foscarnet and cytogam. Day 100 mortality was similar between
the 2 groups (20.7% for nA vs 33.1% for A, P5 0.31). The cumula-
tive incidence of treatment related mortality was higher in group A
(P5 0.02) due to significantly higher incidence of fatal bacterial orfungal infections (52% vs.24%, p5 0.04), with most deaths occur-
ring beyond day 100.
Conclusion: Alemtuzumab is associated with increased transplant
related mortality due to overwhelming bacterial and fungal infec-
tions with no differences in rate of CMV reactivation or fatal
CMV disease.
Non-Alemtuzumab Alemtuzumab
REGIMEN Group (nA) group (A)No OF PATIENTS 29 21
AGE 55 (14-64) 60 (14-60)
DISEASE
AML 8 10
NHL 6 6
MDS 6 2
MM 2 1
CLL 3 0
CML 4 2
PREVIOUS TREATMENT
0-1 8 6
2-3 14 6
.3 7 9
RISK CATEGORY
Low/Intermediate risk 16 11
High risk 13 10Patient Charecteristics.335
COMPLEX KARYOTYPE PREDICTS POOR RESPONSE TO SALVAGE THER-
APY AND INELIGIBILITY FOR REDUCED INTENSITY CONDITIONING
TRANSPLANTATION IN CLL
Jaglowski, S.M.1, Heerema, N.2, Elder, P.1, Scholl, D.1, Hamadani, M.3,
Byrd, J.C.1, Devine, S.1, Andritsos, L.A.1 1The Ohio State University,
Columbus, OH; 2The Ohio State University, Columbus, OH; 3West Vir-
ginia University, Morgantown, WV
Introduction: Allogeneic stem cell transplantation (aSCT) is the
only potentially curative therapeutic option for patients with
CLL. In spite of recent improvements in transplant-related mortal-
ity due to the introduction of reduced-intensity conditioning
(RIC), only a small proportion of patients ultimately undergo
transplantation. An inability to attain a remission is one important
reason why patients are unable to receive a transplant. This study
evaluates metaphase and interphase cytogenetic abnormalities in
patients who were not able to undergo aSCT because of inability
to attain a remission.
Patients and Methods: All patients with CLL referred for a trans-
plant evaluation from January 2003 to the present were included in
this study. Two electronic databases, E-Results and TransChart,
were reviewed to determine which patients were transplanted, and
of those who were not, the reason for not proceeding to aSCT.
The chromosomal profiles of these patients were evaluated.
Results:The results are summarized in Table 1. From January 2003
to the present, 34 patients with CLL were transplanted at our insti-
tution, and 31 were ineligible for transplant because of inability to
attain disease control. The median number of prior treatments in
each group was 2, and the average ages of patients who were trans-
planted and those who were not were 55 and 56.6 years respectively.
Of the 34 patients who underwent transplantation, 12 had a complex
karyotype ($ 3 cytogenetic abnormalities onmetaphase analysis) and
22 had 0-2 karyotypic abnormalities. This contrasts with patients
who could not attain remission: 19 had a complex karyotype and
12 did not (p5 0.03). When cytogenetic abnormalities were further
analyzed, there was no statistically significant influence of other high
risk cytogenetic abnormalities (del 17p13 17 or del 11q22.3) on abil-
ity to proceed to transplant.
Conclusions: Currently, the presence of the del 17p13 is the only
cytogenetic indication for transplant in first remission in patients
with CLL. These data indicate that a complex karyotype may be
an important factor in determining whether a patient will have a suf-
ficient response to salvage therapy to undergo subsequent aSCT.
